ClinicalTrials.gg
CompletedNCT05670106Updated Sep 15, 2026

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC

A Phase 2 interventional study of [177Lu]Lu-PSMA-617 and Best supportive/best standard of care (BS/BSOC) in Metastatic Castration-Resistant Prostate Cancer (mCRPC), sponsored by Novartis Pharmaceuticals. Completed at 17 sites in China. Open to male participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing Lutetium-177 in Prostatic Neoplasms — 8 open to participants now, 10 under way, none of them phase 3. Lutetium-177 · Prostatic Neoplasms.

Enrollment
4th of 14
62 · median 31
Started
2023
with 2 others
Phase 2
3 of 14
1 open now
Registered
3rd of 14
by date
Lead sponsor
4 of 14
Novartis Pharmaceuticals

Among the 14 studies testing Lutetium-177 in Prostatic Neoplasms, this one is the 4th largest by enrollment, is one of 3 that started in 2023, is one of 3 in phase 2, and was the 3rd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

8 of the 14 studies testing Lutetium-177 in Prostatic Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About Lutetium-177

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 100 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing Lutetium-177 in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study was to assess the efficacy, safety, tolerability, Pharmacokinetic(s) (PK) and dosimetry of [177Lu]Lu-PSMA-617 when administered in addition to Best Supportive/Best Standard of Care (BSC/BSoC) in Chinese participants with progressive PSMA-positive mCRPC who received at least 1 novel androgen receptor pathway inhibitor (ARPI) and were previously treated with 1 to 2 taxane regimens. Furthermore, the safety, PK, and dosimetry of [68Ga]Ga-PSMA-11 were assessed.

Data from this study will be used to bridge global pivotal phase III study (VISION, AAA617A12301) and to support China registration of [177Lu]Lu-PSMA-617 as a novel anticancer modality, namely radioligand therapy, in mCRPC.

Read the detailed description

This was a 2-part study:

  1. Main part: Thirty participants with at least 1 measurable lesion by PCWG3-modified RECIST v1.1 criteria were enrolled in the main part. The primary endpoint of confirmed overall response rate (ORR) was analyzed with participants in this part and was assessed via independent centralized review of radiographic images provided by the Investigator and as outlined in PCWG3-modified RECIST v1.1 criteria.
  2. Extension part: The extension part enrolled additional 30 participants with or without measurable lesions following the main part. The secondary endpoints were analyzed with all participants in both main part and extension part.

Screening and enrollment period:

Written informed consent form (ICF) was obtained prior to any screening procedures. All screening procedures described in the Assessment Schedule were completed within 28 days prior to enrollment, except for radiographic imaging assessment, which was done within 21 days prior to enrollment.

The participants were assessed for eligibility and underwent a mandatory [68Ga]Ga-PSMA-11 Positron Emission Tomography (PET)/Computed Tomography (CT) scan to evaluate Prostate-specific Membrane Antigen (PSMA) positivity for eligibility as assessed by central readers. Only participants with PSMA positive cancer and confirmed eligibility criteria were enrolled.

Following completion of all required screening procedures and verifying participant eligibility, the participant was enrolled. [177Lu]Lu-PSMA-617 was ordered in parallel with interactive response technology (IRT) enrollment registration to allow at least 2 weeks to order and deliver [177Lu]Lu-PSMA-617.

Treatment period:

In principle, all participants should begin [177Lu]Lu-PSMA-617 dosing within 14 days after enrollment registration. However, Cycle 1 Day 1 (C1D1) could be delayed by up to an additional 3 days only for unexpected scheduling delays. Participants received 7.4 Gigabecquerel (GBq) (200 Millicuries (mCi)) +/- 10% [177Lu]Lu-PSMA-617 once every 6 weeks for a planned 6 cycles. BSC/BSoC coud be used, including available care for the eligible participants according to best institutional practice. ARPIs (e.,g., abiraterone, etc.) were allowed. BSC/BSoC for each participant was selected at the discretion of the Investigator prior to [177Lu]Lu-PSMA-617 administration, and could be modified over time as needed. BSC/BSoC was administered per the physician's orders according to clinical best practice.

Radiographic imaging (CT with contrast/Magnetic Resonance Imaging (MRI) and bone scan) was done at every 8 weeks (± 4 days) after first dose of [177Lu]Lu-PSMA-617 for the first 24 weeks (independent of dose delays), then every 12 weeks (± 4 days) thereafter and at End of Treatment (EOT) Visit (if not done within 28 days of EOT) until radiographic disease progression confirmed by central reader, death, withdrawal of consent, loss to follow-up, or subject/guardian's decision.

After the last day of study treatment period of [177Lu]Lu-PSMA-617 (i.e. after completion of 6 cycles of treatment OR treatment discontinuation for any reason) [e.g. upon radiographic progression as confirmed by blinded independent centralized review]), the participants have to have an EOT visit performed ≤ 7 days and enter into the Post-treatment Follow-up period.

If a participant withdrew consent for the treatment period of the study, an EOT is supposed to be done and the participant would enter into the Post-treatment Follow-up unless he specifically withdrew consent for post-treatment follow-up.

Post-treatment Follow-up period:

  1. 30-day Safety Follow-up. All treated participants are to have a safety follow-up conducted approximately 30 days after EOT visit.
  2. Long term Follow-up. The long-term follow-up would start after the 30-day Safety follow-up and would last until study completion. If a participant in the long-term follow-up period discontinued treatment for reasons other than BICR-determined radiographic progression, his tumor assessments were required to be performed every 8 weeks after first dose of study treatment for the first 24 weeks (week 9, 17, 25) and then every 12 weeks (week 37, 49, etc) until confirmation of radiographic progression by BICR. The long-term follow-up period also includes the collection of survival and treatment updates, patient reported outcomes (PROs), serious adverse events (suspected to be related to study treatment), as well as blood sampling for hematology, chemistry testing, coagulation, and PSA. The visits are supposed to be carried out every 12 weeks (± 4 weeks) until death, lost to follow-up, withdrawal of consent, opposition to use data/biological samples or study completion, whichever occurs first. This follow-up allows the data collection on medically significant long-term toxicities, such as long-term radiotoxicity.

If the participant withdrew consent for the collection of blood samples, PROs, and imaging assessments during the long-term follow-up, the information on survival, serious adverse events (SAEs) related to study treatment and post-treatment antineoplastic therapy are to be collected.

PK/dosimetry assessments:

Both PK and dosimetry of [68Ga]Ga-PSMA-11 was to be evaluated in at least 10 and up to 12 participants (at least 6 participants in main part). PK and dosimetry of [68Ga]Ga-PSMA-11 could be evaluated in any participant regardless of his PSMA status.

Both PK and dosimetry of [177Lu]Lu-PSMA-617 are to be evaluated in at least 10 and up to 12 participants (at least 6 participants in main part).

Participants who took part in PK and dosimetry evaluation of [177Lu]Lu-PSMA-617 were to take part in the efficacy and safety evaluation together with the other participants. The treatment and assessment procedure followed the same as above.

03

Conditions studied

  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Browse trials for

Keywords

  • Chinese adult male population
  • therapeutic agent lutetium (177Lu) vipivotide tetraxetan
  • AAA617
  • [177Lu]Lu-PSMA-617
  • radiolabeled compound gallium (68Ga) gozetotide
  • [68Ga]Ga-PSMA-11
  • Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
  • Overall Response Rate
  • ORR
  • Prostate-specific Membrane Antigen
  • PSMA
  • Taxane
  • Androgen Receptor Pathway Inhibitor
  • ARPI
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must be obtained before any assessment is performed.
  • Participants must be Chinese male adults >= 18 years of age.
  • Participants must have histological, pathological, and/or cytological confirmation of prostate cancer.
  • Participants must be [68Ga]Ga-PSMA-11 PET/CT scan positive, and eligible as determined by the sponsor's central reader according to the VISION read rules.
  • Participants must have a castrate level of serum/plasma testosterone (\< 50 ng/dl, or \< 1.7 nmol/L).
  • Participants must have received at least one ARPI (such as enzalutamide and/orabiraterone).
  • Participants must have been previously treated with at least 1, but no more than 2 previous taxane regimens.

    • A taxane regimen is defined as a minimum exposure of 2 cycles of a taxane. If a participant has received only 1 taxane regimen, the participant is eligible if: the participants' physician deems him unsuitable to receive a second taxane regimen (e.g., frailty assessed by geriatric or health status evaluation or intolerance, etc.)
  • Documented progressive mCRPC, based on at least 1 of the following criteria:

    • Serum/plasma PSA progression defined as 2 consecutive increases in PSA measured at least 1 week apart, the minimal start value is 2.0 ng/ml
    • Soft-tissue progression defined based on PCWG3-modified v1.1 (Eisenhauer et al 2009, Scher et al 2016)
    • Progression of bone disease: two new lesions; only positivity on the bone scan defines disease to bone (PCWG3 criteria (Scher et al 2016)
  • Participants must have >= 1 metastatic lesion that is present on baseline CT, MRI or bone scan imaging obtained =\< 21 days prior to enrollment via central reading.

    • In main part: participant must have at least one by PCWG3-modified RECIST v1.1 via central reading
  • Participants must have adequate organ function:

    • Bone marrow reserve:
    • White blood cell (WBC) count >= 2.5 × 109/L OR (ANC) >= 1.5 × 109/L
    • >=100 × 109/L
    • >= 9 g/dL
    • Hepatic:
    • Total =\< 1.5 x the institutional (ULN). For participants with known Gilbert's Syndrome =\< 3 × ULN is permitted
    • (ALT) or aspartate aminotransferase (AST) =\< 3.0 × ULN OR =\< 5.0 × ULN for participants with liver metastases
    • Renal:
    • >= 50 mL/min/1.73m2 using the Modification of Diet in Renal Disease (MDRD) equation
  • Albumin >3.0 g/dL.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223 or hemi-body irradiation.
  • Previous PSMA-targeted radioligand therapy.
  • Any systemic anti-cancer therapy (e.g. chemotherapy, immunotherapy or biological therapy [including monoclonal antibodies], APRI is not included) within 28 days prior to day of enrollment.
  • Any agents (e.g. poly adenosine diphosphate-ribosyl polymerase inhibitors [PARPi]) within 28 days prior to day of enrollment.
  • History of to any of the study drugs or its or to drugs of similar chemical classes.
  • Other concurrent cytotoxic chemotherapy, immunotherapy, radioligand therapy, or investigational therapy.
  • Transfusion for the sole purpose of making a subject eligible for study inclusion.
  • Participants with a history of central nervous system (CNS) who are neurologically unstable, symptomatic, or receiving for the purpose of maintaining neurologic integrity.

    • Participants with are eligible if received therapy (surgery, radiotherapy, gamma knife), asymptomatic and neurologically stable without corticosteroids.
    • Participants with epidural disease, canal disease and prior cord involvement are eligible if those areas have been treated, are stable, and not neurologically impaired.
  • Symptomatic spinal cord compression, or clinical or radiologic findings indicative of impending cord compression.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    [177Lu]Lu-PSMA-617 plus best supportive/best standard of care (BS/BSOC)

    Patients received the investigational product 7.4 GBq (+/- 10%) 177Lu-PSMA-617 intravenously every 6 weeks (+/- 1 week) for a maximum of 6 cycles. Best supportive/best standard of care (BS/BSOC) could be used.

    Drug: [177Lu]Lu-PSMA-617 · Other: Best supportive/best standard of care (BS/BSOC) · Drug: 68Ga-PSMA-11

Interventions

  • Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles.

    Also known as: AAA617

  • OtherBest supportive/best standard of care (BS/BSOC)

    Best supportive/best standard of care as defined by the local investigator

  • Administered single intravenous dose of approximately 150 MBq. Administered dose could not be lower than 111 MBq or higher than 259 MBq (3 - 7 mCi).

06

What researchers measure

Primary outcomes

  1. Main part: Confirmed Overall Response Rate (ORR) per Blinded Independent Central Review (BICR)

    Confirmed Overall Response Rate (ORR) is defined as the proportion of participants with Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR). ORR is based on PCWG3-modified RECIST v1.1 response for patients with measurable disease at baseline.

    Time frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, approx. 1 year

Secondary outcomes

  1. Main & extension parts: Radiographic progression free survival (rPFS)

    rPFS is defined as the time (in months) from the date of enrollment to the date of radiographic progression as outlined in PCWG3 guideline or death due to any cause.

    Time frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first.

  2. Main & extension parts: Overall survival (OS)

    Overall survival (OS) is defined as the time(in months) from the date of enrollment to the date of death due to any cause. If a participant is not known to have died, then OS will be censored at the latest date the participant was known to be alive (on or before the cut-off date).

    Time frame: From date of randomization until date of death from any cause.

  3. Main & extension parts: Overall response rate (ORR)

    Overall response rate (ORR)is defined as the proportion of participants with best overall response of complete response or partial response, as per central and local review according to PCWG3 modified RECIST 1.1

    Time frame: From date of randomization till radiographic progression or date of death from any cause.

  4. Main & extension parts: Disease control rate (DCR)

    Disease control rate (DCR) is defined as the proportion of participants with best overall response of complete response or partial response or Stable disease, or non-CR/non-PD, as per central and local review and according to PCWG3-modified RECIST v1.1.

    Time frame: From date of randomization till radiographic progression or date of death from any cause.

  5. Main & extension parts: Duration of response (DOR)

    Duration of response (DOR) is defined as the time (in months) from the date of the first documented response (CR or PR) to the date of first documented progression according to PCWG3-modified RECIST v1.1 or death due to any cause, among participants with a confirmed response.

    Time frame: From date of randomization until date of progression or date of death from any cause.

  6. Main & extension parts: Time to a first symptomatic skeletal event (TTSSE)

    TTSSE is defined as the time (in months) from the date of enrollment to the date of SSE or death due to any cause. The SSE date is date of the first new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, requirement for radiation therapy to relieve bone pain, or death due to any cause, whichever comes first.

    Time frame: From date of randomization till date of a first SSE or date of death from any cause.

  7. Main & extension parts: PSA50 response rate

    PSA response rate is the proportion of PSA responders, defined as a participant who has achieved PSA decrease of \>= 50% from baseline that is confirmed by a second consecutive PSA measurement \>= 4 weeks later.

    Time frame: From date of randomization till end of long-term FU.

  8. Main & extension parts: Progression Free Survival (PFS)

    PFS (Radiographic/clinical/PSA progression) is defined as the time (in months) from the date of enrollment to the date of radiographic, clinical or PSA progression free survival, or death due to any cause, whichever occurs first.

    Time frame: From date of randomization until date of progression or date of death from any cause, whichever come first.

  9. Main & extension parts: European Quality of Life (EuroQol) - 5 Domain 5 Level scale (EQ-5D- 5L)

    FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT- General + the Prostate Cancer Subscale (PCS). The FACTGeneral (FACT-G) is a 27 item Quality of Life (QoL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional Well-being (0-24). The total score range is between 1-108, higher scores indicates better for total score and subscale scores. PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better). The FACT-P total score is the sum of all 5 subscale scores of the FACT-P questionnaire and ranges from 0-156. Higher scores indicate higher degree of functioning and better quality of life.

    Time frame: From date of randomization till the end of long term FU

  10. Main & extension parts: Functional Assessment of Cancer Therapy - Prostate (FACT-P) Questionnaire

    FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT- General + the Prostate Cancer Subscale (PCS). The FACTGeneral (FACT-G) is a 27 item Quality of Life (QoL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional Well-being (0-24). The total score range is between 1-108, higher scores indicates better for total score and subscale scores. PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better). The FACT-P total score is the sum of all 5 subscale scores of the FACT-P questionnaire and ranges from 0-156. Higher scores indicate higher degree of functioning and better quality of life.

    Time frame: From date of randomization till 30 day safety follow-up or at the end of long term FU for patients prematurely discontinued, assessed up to 57 months (estimated final OS analysis)

  11. Main & extension parts: Brief Pain Inventory - Short Form (BPI-SF) Questionnaire

    The BPI-SF is a publicly available instrument to assess the pain and includes severity and interference scores. BPI-SF is an 11-item selfreport questionnaire that is designed to assess the severity and impact of pain on daily functions of a participant. Pain severity score is a mean value for BPI-SF questions 3, 4, 5 and 6 (questions inquiring about the extent of pain, where the extent is ranked from 0 \[no pain\] to 10 \[pain as bad as you can imagine\]). Pain severity progression is defined as an increase in score of 30% or greater from baseline without decrease in analgesic use.

    Time frame: From date of randomization till the end of long term FU

  12. Main & extension parts: Number of Participants with Treatment Emergent Adverse Events

    The distribution of adverse events will be done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs) and Serious Adverse Event (TESAEs), through the monitoring of relevant clinical and laboratory safety parameters.

    Time frame: From day of the first administration of study treatment to 30 days after EOT or to the last [177Lu]Lu-PSMA-617 dose date + 41 days, whichever is later.

  13. Main & extension parts: Area under the blood concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) of [177Lu]Lu-PSMA-617

    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization of \[177Lu\]Lu-PSMA-617 in at least 10 and up to 14 patients. AUClast will be listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Week 1(Day 1) and Cycle 1 Week 2(Day 8): Pre dose, 0(End of infusion), 20 & 60 mins(+/- 5 mins), 2 & 4 hours(+/-30 mins), 24 hours(+/- 2 hr), 48 hours(+/- 4 hr), 72 hours(+/- 6 hr), 168 hours(+/- 12 hr) from the end of infusion (1 cycle=42 days)

  14. Main & extension parts: Observed maximum blood concentration (Cmax) of [177Lu]Lu-PSMA-617

    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization of \[177Lu\]Lu-PSMA-617 in at least 10 and up to 14 patients. Cmax will be listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Week 1(Day 1) and Cycle 1 Week 2(Day 8): Pre dose, 0(End of infusion), 20 & 60 mins(+/- 5 mins), 2 & 4 hours(+/-30 mins), 24 hours(+/- 2 hr), 48 hours(+/- 4 hr), 72 hours(+/- 6 hr), 168 hours(+/- 12 hr) from the end of infusion (1 cycle=42 days)

  15. Main & extension parts: Blood concentration of [177Lu]Lu-PSMA-617

    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization of \[177Lu\]Lu-PSMA-617 in at least 10 and up to 14 patients. Blood concentration of \[177Lu\]Lu-PSMA-617 will be summarized with descriptive statistics.

    Time frame: Cycle 1 Week 1(Day 1) and Cycle 1 Week 2(Day 8): Pre dose, 0(End of infusion), 20 & 60 mins(+/- 5 mins), 2 & 4 hours(+/-30 mins), 24 hours(+/- 2 hr), 48 hours(+/- 4 hr), 72 hours(+/- 6 hr), 168 hours(+/- 12 hr) from the end of infusion (1 cycle=42 days)

  16. Main & extension parts: Organ absorbed dose of [177Lu]Lu-PSMA-617

    The quantity of ionizing radiation absorbed by organs and tissues will be summarized with descriptive statistics.

    Time frame: Cycle 1 Week 1(Day 1) and Cycle 1 Week 2(Day 8): 1~2 & 4 hours, 18~26 hours, 48 hours(+/- 12 hr), 168 hours(+/- 12 hr) from the end of infusion (1 cycle=42 days)

  17. Main & extension parts: Area under the blood concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) of [68Ga]Ga-PSMA-11

    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization of \[68Ga\]Ga-PSMA-11 in at least 10 and up to 14 patients. AUClast will be listed and summarized using descriptive statistics.

    Time frame: Screening (Day -42 to Day -14) : 5 mins (+/- 3 mins), 15 & 30 & 45 mins (+/- 5 mins), 85 mins (+/- 10 mins), 175 & 245 mins (+/- 30 mins) from the end of infusion

  18. Main & extension parts: Observed maximum blood concentration (Cmax) of [68Ga]Ga-PSMA-11

    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization of \[68Ga\]Ga-PSMA-11 in at least 10 and up to 14 patients. Cmax will be listed and summarized using descriptive statistics.

    Time frame: Screening (Day -42 to Day -14) : 5 mins (+/- 3 mins), 15 & 30 & 45 mins (+/- 5 mins), 85 mins (+/- 10 mins), 175 & 245 mins (+/- 30 mins) from the end of infusion

  19. Main & extension parts: Blood concentration of [68Ga]Ga-PSMA-11

    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization of \[68Ga\]Ga-PSMA-11 in at least 10 and up to 14 patients. Blood concentration of \[68Ga\]Ga-PSMA-11 will be summarized with descriptive statistics.

    Time frame: Screening (Day -42 to Day -14) : 5 mins (+/- 3 mins), 15 & 30 & 45 mins (+/- 5 mins), 85 mins (+/- 10 mins), 175 & 245 mins (+/- 30 mins) from the end of infusion

  20. Main & extension parts: Organ absorbed dose of [68Ga]Ga-PSMA-11

    The quantity of ionizing radiation absorbed by organs and tissues will be summarized with descriptive statistics.

    Time frame: Screening (Day -42 to Day -14): 30 mins (+/- 5 mins), 60 mins (+/- 10 mins), 120 mins (+/- 20 mins) and 255 mins (+/- 30 mins) from the end of infusion

07

Study locations

17 sites
  • Novartis Investigative Site
    Guangzhou, Guangdong 510120, China
  • Novartis Investigative Site
    Zhengzhou, Henan 450003, China
  • Novartis Investigative Site
    Zhengzhou, Henan 450008, China
  • Novartis Investigative Site
    Wuhan, Hubei 430022, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210006, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210029, China
  • Novartis Investigative Site
    Xian, Shanxi 710032, China
  • Novartis Investigative Site
    Xian, Shanxi 710061, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Beijing, 100034, China
  • Novartis Investigative Site
    Beijing, 100036, China
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Guangzhou, 510060, China
  • Novartis Investigative Site
    Shanghai, 200025, China
  • Novartis Investigative Site
    Shanghai, 200032, China
  • Novartis Investigative Site
    Shanghai, 200080, China
  • Novartis Investigative Site
    Tianjin, 300300, China
08

References and documents

Publications

  • Shi H, Guo J, Fan W, Li Y, Huang R, Dong Q, Yang Z, Yang Y, Wang X, Gu D, Huo L, Ji Z, Wang F, Xu D, Jiang Z, Li H, Li J, Li R, Qi L, Wang J, Ye D. A phase II study evaluating pharmacokinetics and dosimetry of 177Lu-PSMA-617 radioligand therapy in Chinese participants with progressive metastatic castration-resistant prostate cancer. EJNMMI Res. 2026 Mar 1;16(1):55. doi: 10.1186/s13550-026-01401-3. PubMed 41764712 ↗

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in May 2024, 12 months.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 12 months is below that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2022
First posted
Jan 4, 2023
StartActual
May 16, 2023
Primary completionActual
May 17, 2024
CompletionActual
Apr 22, 2026
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05670106
Responsible party
Sponsor
First posted
Jan 4, 2023
Start date
May 16, 2023
Primary completion
May 17, 2024
Completion
Apr 22, 2026
Last update
Sep 15, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutetium-177

Start the discussion